60 likes | 331 Views
E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL). Stratification 0-2 vs 3-7 adverse factors * Locally extensive vs Stage III/IV. ABVD x 6-8 + IFRT (36 Gy) to bulky mediastinal lesions. Outcomes
E N D
E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in LocallyExtensive and AdvancedStageHodgkinLymphoma (HL) Stratification 0-2 vs 3-7 adverse factors* Locallyextensive vs Stage III/IV ABVD x 6-8 + IFRT (36 Gy) tobulkymediastinallesions Outcomes Failure-Free Survival(FFS)** OverallSurvival (OS) UntreatedStage III/IV, orLocallyExtensive (>1/3 mediastinum) HL n=428 R Stanford V + IFRT (36 Gy) tolesions >5 cm FFS: Time from randomization to progression, relapse or death, whichever occurred first n=854 n=426 1/2 Gordon LI, et al. ECOG 2496, J Clin Oncol DOI: 10.1200/JCO.2012.43.4803 Creada por: Mauricio Lema Medina MD
E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in LocallyExtensive and AdvancedStageHodgkinLymphoma (HL) % ABVD remains the standard of care for patients with advanced Hodgkin lymphoma. 2/2 Gordon LI, et al. ECOG 2496, J Clin Oncol DOI: 10.1200/JCO.2012.43.4803 Creada por: Mauricio Lema Medina MD
Treatment of AdvancedHodgkinLymphoma: The More ThingsChange, the More TheyStaytheSame Longo DL. J ClinOncolDOI:10.1200/JCO.2012.44.7235